<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913233</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0199</org_study_id>
    <nct_id>NCT04913233</nct_id>
  </id_info>
  <brief_title>Establishment and Clinical Validation of New Technologies for Accurate Screening of Colorectal Cancer Based on Multi-omics</brief_title>
  <official_title>Research on New Technologies for Screening and Early Diagnosis of Malignant Tumors - Establishment and Clinical Validation of New Technologies for Accurate Screening of Colorectal Cancer Based on Multi-omics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      The current screening techniques for colorectal cancer include colonoscopy, fecal occult&#xD;
      blood, and high-risk factor questionnaires. However, the colorectal cancer screening&#xD;
      technology that has been widely used at present cannot take into account sensitivity and&#xD;
      specificity, and the tumor detection rate is low.&#xD;
&#xD;
      The purpose of research:&#xD;
&#xD;
        1. Build a new type of population colorectal cancer precision screening technology program;&#xD;
&#xD;
        2. Improve the detection rate of colorectal cancer in the population by new methods&#xD;
           (compared with the existing domestic advanced technology) by ≥20%, and improve the&#xD;
           specificity of colorectal cancer screening by ≥15% without significantly reducing the&#xD;
           sensitivity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Colorectal cancer detection rate in the population</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Colorectal cancer detection rate in the population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Colorectal cancer screening specificity</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Colorectal cancer screening specificity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Colorectal cancer screening sensitivity</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Colorectal cancer screening sensitivity</description>
  </primary_outcome>
  <enrollment type="Anticipated">9000</enrollment>
  <condition>Colorectal Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals of 40-74 years old in non-high incidence of colorectal cancer areas(hospital&#xD;
        outpatient population, community population in non-high-risk areas) .&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age: 40-74 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Combine severe disorders to make it unsuitable for colonoscopy&#xD;
&#xD;
          2. Combine other tumors&#xD;
&#xD;
          3. Mental and behavioral abnormalities do not cooperate with the screener&#xD;
&#xD;
          4. Researchers believe that other reasons are not suitable for enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Yuan</last_name>
    <phone>+8613858193601</phone>
    <email>yuanying1999@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanqin Huang</last_name>
    <phone>+8613588418080</phone>
    <email>13588418080@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese Medicine Hospital of Haining City, Haining Cancer Preventional and Treatment Research Institute</name>
      <address>
        <city>Haining</city>
        <state>Zhejiang</state>
        <zip>314400</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weihua Ma</last_name>
      <email>672682815@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiashan County Cancer Prevention and Treatment Institute</name>
      <address>
        <city>Jiashan</city>
        <state>Zhejiang</state>
        <zip>314100</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xinglin Fei</last_name>
      <email>feixl711@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lanxi City People's Hospital, Linjiang Hospital</name>
      <address>
        <city>Lanxi</city>
        <state>Zhejiang</state>
        <zip>321100</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weifang Zheng</last_name>
      <email>2609276435@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>May 30, 2021</last_update_submitted>
  <last_update_submitted_qc>May 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Cancer Screening</keyword>
  <keyword>Colonoscopy</keyword>
  <keyword>APCS</keyword>
  <keyword>HRFQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

